Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

Ovarian Neoplasms Clinical Trial

Official title:

A Single-arm, Exploratory Study of Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05753826
• Other study ID #: 23-OBU-FJ-OC-II-003
• Status: Recruiting
• Phase: Phase 2
• Start date: August 1, 2023
• Est. completion date: December 31, 2027

Study information

• Verified date: October 2023
• Source: Fujian Cancer Hospital
• Contact: Yang Sun, Doctor
• Phone: 15959028989
• Email: garyhanyu[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm, exploratory study. People with recurrent platinum-resistant ovarian cancer who have not received any previous systemic antitumor therapy for ovarian cancer were selected to evaluate the efficacy and safety of adebrelimab combined with fuzuloparib.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 37
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Age 18-70;Female;

2. Pathologically (including histologically) confirmed epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (hereinafter referred to as ovarian cancer), recurrence within less than 6 months after the last treatment with platinum-containing chemotherapy;

3. Patients have at least one target lesion with measurable dimensions according to RECIST1.1 criteria;

4. HRR gene mutation confirmed by testing tissue or blood samples;

5. ECOG PS 0-1;

6. Major organ functions are normal and meet the following criteria:(1) Blood routine inspection standards must meet: (no blood transfusion within 14 days)a.HB=100g/L, b. WBC=3×10^9/L c. ANC=1.5×10^9/L, d.PLT=100×10^9/L; (2) Biochemical examination must meet the following standards: a. BIL =1.5 times the upper limit of normal (ULN); b. ALT and AST=2.5×ULN, ALT and AST=5×ULN in patients with liver metastases; c. Serum Cr=1.5×ULN

7. Activated partial thromboplastin time (APTT) = 1.5 times ULN, prothrombin time (PT) = 1.5 times ULN, international normalized ratio (INR) = 1.5 times ULN, unless the patient is receiving anticoagulation, as long as PT or APTT is within the expected range of anticoagulant use;

8. No severe heart, lung, liver or kidney disorders;

9. Women of childbearing age must have a pregnancy test (serum) within 7 days prior to enrollment and have a negative result, and be willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the test drug;

10. Estimated survival= 12 weeks;

11. Sign a written informed consent form and be able to comply with the visitation and related procedures set out in the programme.

Exclusion Criteria:

1. Other clinical drug experiments in which other experimental research drugs are used concurrently with the study;

2. Patients with known hypersensitivity to fluzoparib or hypersensitivity to drug-active or inactive ingredients with a similar chemical structure to fluzoparib;

3. Patients with known hypersensitivity to adebrelimab or hypersensitivity to the active or inactive components of the drug having a similar chemical structure to adebrelimab;

4. Inability to swallow oral medications and any gastrointestinal disorders that may interfere with the absorption and metabolism of study medications, such as uncontrolled nausea and vomiting, gastrointestinal obstruction or malabsorption;

5. prior treatment with known or probable immune checkpoint inhibitors;

6. Have any active autoimmune disease or history of autoimmune disease (e.g., interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); Except vitiligo or recovered childhood asthma/allergies who do not require any intervention in adulthood; Autoimmune-mediated hypothyroidism treated with stable doses of thyroid-replacement hormones; Type I diabetes mellitus with a stable dose of insulin;

7. A history of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation and allogeneic bone marrow transplantation;

8. With unstable systemic diseases, such as hypertension that cannot be well controlled by antihypertensive drugs (systolic blood pressure = 140 mmHg or diastolic blood pressure =90 mmHg), severe arrhythmias, etc.;

9. Previous or current idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, organising pneumonia, drug-induced pneumonia, or active pneumonia on screening-phase CT;

10. There are cardiac clinical symptoms or diseases that are not well controlled, such as:

(1) cardiac insufficiency above NYHA grade 2 (2) unstable angina (3) acute myocardial infarction within 1 year (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention (5) QTc>470ms;

11. Patients who are pregnant or breastfeeding, or who plan to become pregnant during study treatment;

12. The investigators considered it unsuitable for inclusion.

Related Conditions & MeSH terms

• Ovarian Diseases
• Ovarian Neoplasms

Intervention

Drug:
• Adebrelimab
20mg/kg,D1,q3W
• Fuzuloparib
100 mg bid

Locations

Country	Name	City	State
China	Fujian Cancer Hospital	Fujian

Sponsors (1)

Lead Sponsor	Collaborator
Fujian Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate(ORR)	ORR is determined using RECIST v1.1, Defined as the optimal overall response (CR or PR) at the time point assessed from enrollment to the end of neoadjuvant therapy	3 years
Secondary	Overall survival(OS)	Defined as the time from the enrollment to death from any cause	3 years
Secondary	Progression free survival(PFS)	It is defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first.	3 years
Secondary	Disease Control Rate(DCR)	DCR is determined using RECIST v1.1, Defined as the rate of disease control (CR or PR or SD) from enrollment to the end of neoadjuvant therapy.	3 years